Healios

Focus: Healios is a Japan-based stem cell regenerative medicine biotech focused on cell therapy platforms, particularly the MultiStem® program targeting critical care and cardiovascular indications. The company operates as a mid-cap biotech with a diversified pipeline spanning stroke, cardiac, pulmonary, and trauma applications.

Cell Therapy

Profile data last refreshed Yesterday · AI intelligence enriched 2w ago

Open Jobs

About Healios

AI assessmentNot Hiring

No open roles listed right now. Follow Healios to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

1/9 — Limited

Company HealthSolid

Pipeline

Mid-stage

2 Phase 3+

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Pipeline & Clinical Trials

Resilience-Based Program for Support Partners of PwMS

Multiple Sclerosis

N/A

AMI MultiStem®

Acute Myocardial Infarction

Phase 1

Clinical Trials (1)

Help build intelligence for Healios

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Access to cutting-edge stem cell and cell therapy platform (MultiStem) with applications across 9+ indications including Phase 3 programs in stroke and ARDS
Significant pipeline depth with 14 active trials across Phase 1-3, offering diverse career exposure to early-stage discovery through late-stage development
Japan-based headquarters provides unique geographic advantage and potential exposure to Asian regulatory pathways and market expansion

Watch Out For

Very limited current hiring (1 active R&D role) signals minimal near-term growth or organizational expansion opportunities
Cell therapy manufacturing complexity and regulatory uncertainty create execution risk; no approved products indicate pre-revenue stage with extended cash burn trajectory

Generated by Claude from Healios's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.